23andMe Reports Q1 Revenue Drop, Narrows Losses
23andMe's Q1 revenue declines by 34% but narrows losses. Focus on AI and genetic studies drives future growth.
- Latest
- Trending
23andMe's Q1 revenue declines by 34% but narrows losses. Focus on AI and genetic studies drives future growth.
E3technology enhances Empore™ membranes for better proteome sample prep, crucial for low-cell proteomics, say experts at UD and CDS Analytical.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.